Skip to Main Content

Does “The Art of the Deal” cover vaccines? Is patient privacy a relic of the past? And how big can biotech get in China?

We discuss all that and more on this, the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the ongoing coronavirus outbreak, the White House’s response, and what drug companies are doing to potentially help. Then, STAT’s Erin Brodwin joins us to discuss how Big Tech’s appetite for patient data has problematic implications for privacy. Finally, STAT’s China health care writer Jonathan Chan calls in from Hong Kong to discuss China’s fast-growing biotech industry and the challenges it faces ahead.


For more on what we cover, here’s the latest on the coronavirus; here’s the news on Google and patient data; and here’s where you can sign up for STAT’s China newsletter.

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple PodcastsStitcherGoogle Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].

  • And the natural antiviral approaches are?
    Who is economically incented to share them?
    Who knows them?
    Are most doing some by accident?
    Maybe it could be done if they got disguised as something else, internally then externally, with a company name that drains the jungle, and a leader who thinks for the long term, and who gets welcomed to the healthcare jungle.
    I wonder whether “health benefits” is the feint, acquisition, stack & not sickness benefits.
    This could get interesting. Seems to me.

Comments are closed.